Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Duke University Medical Center

Headquarters: Durham, NC, United States of America
Year Founded: 1930
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Dec 16, 2024
Distillery Therapeutics

Inhibiting SUMOylation for inflammatory bowel disease

BioCentury | Apr 9, 2024
Discovery & Translation

AACR brings new modalities, new targets to glioblastoma

BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for
BioCentury | Mar 16, 2023
Data Byte

Translational spotlight on variant-proofing tech for COVID and beyond

Host targets and antiviral strategies with efficacy across multiple viruses in BioCentury’s Distillery
BioCentury | Oct 7, 2022
Discovery & Translation

Galixir’s rapid PROTAC design; plus Engimmune’s TCR platform and more

BioCentury’s roundup of translational news
BioCentury | Apr 1, 2022
Distillery Therapeutics

Small molecule ghrelin receptor agonist for hyperdopaminergia

BioCentury | Feb 10, 2022
Discovery & Translation

Translational trendspotting: a Distillery dive into neurology

Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Feb 9, 2022
Discovery & Translation

Translational trendspotting: a Distillery dive into infectious disease

Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery
BioCentury | Dec 3, 2021
Distillery Therapeutics

Targeting CTNND2 phosphorylation for neuropathic pain

BioCentury | Dec 3, 2021
Distillery Therapeutics

HIV protease inhibitors for dystonia

Items per page:
1 - 10 of 180